Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — FY2022 Earnings Presentation
26 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, April 2023
Slide 1: 2022 Annual Results Presentation
2022 Annual Results Presentation Zylox-Tonbridge April 2022
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: 2022 Business Review
2022 Business Review Financial Highlights Sales Highlights R&D Highlights 334 million RMB Revenue Continue to cultivate the domestic market 52 Number of NMPA registration approvals + 87.8% Growth obtained in 2022 • High-frequency Professional Gross Profit 75.6% Academic Marketing Activites Margin •
Slide 4: Financial Highlights
Financial Highlights Rapid Growth Efficiency Improvement
Slide 5: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth from 2020 to 2022 Overseas Revenue from 2020 to 2022 GPM Improves with Sales Optimization and Scale Effect （RMB in millions） （RMB in millions） （RMB in millions） Three-year CAGR：248% Three-year CAGR：53% Thr
Slide 6: Neurovascular - Rapid Revenue Growth
Neurovascular - Rapid Revenue Growth Revenue of Neurovascular Products Main Source of Revenue （ RMB in thousand） % of Revenue: 72.2% 63.1% 69.9% Clot Retriever Device Intracranial Support Catheter 250,000 233,398 200,000 108% Intracranial Balloon Neurovascular Catheter(Rx) Embolization Coils Other L
Slide 7: Peripheral-vascular - Steady Revenue Growth
Peripheral-vascular - Steady Revenue Growth Revenue of Peripheral-vascular Products Main Source of Revenue （ RMB in thousands） % of Revenue : 27.8% Drug Coated High Pressure PTA 36.9% 30.1% PTA Balloon Balloon Catheter Catheter 120,000 100,692 100,000 PTA Balloon Snare Retrieval Kit 53% Catheter for
Slide 8: Increasing Operating Expenses Level in Line with Development
Increasing Operating Expenses Level in Line with Development Selling and Distribution Expenses R&D Expenses Administrative Expenses （ RMB in thousands ） （ RMB in thousands ） （ RMB in thousands ） % of Revenue : 74% 54% 42% 261% 94% 70% 112% 57% 33% 233,461 168,100 140,137 109,337 95,268 100,599 72,06
Slide 9: Sales Scale and Operational Efficiency, the Trend of Profits Emerged
With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged Other Non-operating Income and Expenses Adjusted Net Profit / (Loss )3 （ RMB in thousands ） （ RMB in thousands ） 2020 2021 2022 2020 2021 2022 140000 0 (25,877) 120000 (77,357) -50,000 (100,745) 1
Slide 10: Sufficient Cash and Efficient Operations to Support Rapid Growth
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years 2022 Cash Status Trade Receivables Turnover Trade Payables Turnover （ RMB in thousands ） （ Turnover Days ） （ Turnover Days ） 2,928,874 107 2,693,107 73 55 7.44 (24,644) 3,568 0.58 0.79 2020 2021 2022 2020 2021 2022
Slide 11: Sales and Marketing
Sales and Marketing Step by Step Embraced the Volume- based Procurement (VBP)
Slide 12: Deeply Cultivate the Domestic Market and Build a Wide-ranging Sales Network
Deeply Cultivate the Domestic Market and Build a Wide-ranging Sales Network Steady Expansion of the Sales Marketing Team Supports the Rapid commercialization capabilities Rapid Development Numbers of Provincial Procurement Platforms that Products are Included into as of December 31, 2022 Number of S
Slide 13: Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio
Professional Academic Marketing Strategy – Neurovascular Interventional Portfolio In-depth case studies newsletter & Surgery live broadcast event ： • published 61 cases（5+ cases / month）; Covered ischemic \ hemorrhagic \ intracranial stenosis topics and products; • opened 「Shen’Jie’Guo’Chao(神介国潮)」 s
Slide 14: Professional Academic Marketing Strategy – Peripheral-vascular Interventional Portfolio
Professional Academic Marketing Strategy – Peripheral-vascular Interventional Portfolio Actively exert expertise and build an academic communication platform： • Zylox Institute「Yuan’Xing(远行)」series activities held 10 sessions and involved 500 people. High-frequency domestic online meetings to exchan
Slide 15: Neurovascular Embolization Coils Quickly Achieve Multi-province Admission Through VBP
Neurovascular Embolization Coils Quickly Achieve Multi-province Admission Through VBP Winning bids for various types of VBP in 2022 The Anhui Provincial VBP categorized in the Group A4 in December 2022 The Jiangsu Provincial VBP Categorized 1st place in the Group 21 The 21-province alliance VBP in
Slide 16: R&D Steady and Innovative
SY sauiaat R&D Steady and Innovative
Slide 17: Robust R&D Pipelines Bolster the Long-term Growth
Robust R&D Pipelines Bolster the Long-term Growth Expect to launch 561 products 28 26 2 in total domestically in the Neurovascular Peripheral-vascular Vascular Closure upcoming 3 years Interventional Products Interventional Products Devices As of December,31 2023 2024 2025 2022 19 approved products
Slide 18: Peripheral-vascular Overseas Product Pipelines
Enrich Overseas Product Pipelines Increase Investment in Overseas Markets Phase Expected Commercial Registration & Launch France Preclinical Clinical Trials Products Approva Year Exempted from clinical ZENFLUXION® Drug Coated PTA Italy trial requirement CE Launched Balloon Catheter ZENFLUXION® Drug
Slide 19: Neurovascular – Key Products Expected to be Launched within the Following Years
Neurovascular – Key Products Expected to be Launched within the Following Years Second Generation Aspiration Catheter Flow Diverter Clot Retriever Device Effects:： Effects:： Effects:： • Expected to be used for • Expected to be used for the treatment • Expected to be used for the treatment of revascu
Slide 20: Peripheral-vascular – Key Products Expected to be Launched within the Following Years
Peripheral-vascular– Key Products Expected to be Launched within the Following Years Peripheral Venous Peripheral Detachable Fibered Suture-mediated Stent System Embolization Coils Closure System Effects ： Effects ： Effects ： • For the treatment of iliac vein • Used to block or reduce blood flow rat
Slide 21: In-house R&D Technology Platforms Solidify the Competitive Advantages
In-house R&D Technology Platforms Solidify the Competitive Advantages During the Full Product Life Cycle • Complete balloon molding, laser • Ability to process stents in the welding, pleating/folding & final whole process from precision assembly lines laser cutting, heat treatment • Can produce a va
Slide 22: 2023 Carry Out the Mission, Continue to Enhance Our Industry Leadership
2023 Carry Out the Mission, Regardless Challenges Continue to Enhance Our Industry Leadership 1 Increase market share • Further increase the number of hospitals covered; • Continue to focus on both of hospitals in lower-tier cities’ sinking market and those in key areas; • Actively prepare for VBP,
Slide 23: Appendix
APPENDIX Please refer to 2022 Annual Report for further information Click to download the 2022 Annual Report
Slide 24: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 % of % of % of RMB’000 2020 Revenue 2021 Revenue 2022 Revenue Revenue 27,631 100% 177,912 100% 334,090 100% Cost of sales -11,344 -41% -46,031 -26% -81,421 -24% Gross Profit 16,287 59% 131,881 100% 252,669 76% Selling and distribution
Slide 25: Consolidated Balance Sheet
Consolidated Balance Sheet Year ended December 31 RMB’000 2020 2021 2022 Non-current assets Property, plant and equipment 105,224 178,270 290,243 Right-of-use assets 16,950 34,115 48,136 Intangible assets 7,556 4,889 9,637 Prepayments 4,099 6,804 10,645 Financial assets at fair value through profit
Slide 26: Consolidated Balance Sheet
Consolidated Balance Sheet Year ended December 31 RMB’000 2020 2021 2022 Non-current liabilities Lease liabilities 1,396 6,509 7,459 Borrowings 26,250 - - Total non-current liabilities 27,646 6,509 7,459 Current liabilities Short-term borrowings 3,750 0 0 Trade and other payables 43,658 86,307 126,6
Zylox-Tonbridge Medical Technology — FY2022 Earnings Presentation on 6ix